Fuji Pharma (TSE:4554) Full Year 2024 Results
Key Financial Results
- Revenue: JP¥46.1b (up 13% from FY 2023).
- Net income: JP¥6.15b (up 79% from FY 2023).
- Profit margin: 13% (up from 8.4% in FY 2023).
- EPS: JP¥253 (up from JP¥141 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Fuji Pharma EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.0%.
Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan.
Performance of the Japanese Pharmaceuticals industry.
The company's shares are up 5.4% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 4 warning signs for Fuji Pharma (of which 2 don't sit too well with us!) you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4554
Fuji Pharma
Engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally.
Proven track record average dividend payer.
